2011 Update of the Drug Resistance Mutations in HIV-1

Overview

Journal Top Antivir Med

Specialties Infectious Diseases
Microbiology

Date 2011 Dec 14

PMID 22156218

Citations 155

Authors

Victoria A Johnson

Vincent Calvez

Huldrych F Gunthard

Roger Paredes

Deenan Pillay

Robert Shafer

Annemarie M Wensing

Douglas D Richman

Affiliations

Soon will be listed here.

Abstract

This November 2011 edition of the IAS-USA drug resistance mutations list updates the figures last published in December 2010 (Johnson VA et al, Top HIV Med, 2010;18:156-163).

Citing Articles

Eco-Friendly Species (L.) Ach.: Phenolic Profile, Antioxidant, Anti-inflammatory, and Anticancer Properties.

Belhouala K, Korkmaz C, Tas Kucukaydin M, Kucukaydin S, Duru M, Benarba B ACS Omega. 2024; 9(46):45719-45732.

PMID: 39583657 PMC: 11579742. DOI: 10.1021/acsomega.3c10407.

Development and emerging trends of drug resistance mutations in HIV: a bibliometric analysis based on CiteSpace.

Chen X, Chen X, Lai Y Front Microbiol. 2024; 15:1374582.

PMID: 38812690 PMC: 11133539. DOI: 10.3389/fmicb.2024.1374582.

Applying Next-Generation Sequencing to Track HIV-1 Drug Resistance Mutations Circulating in Portugal.

Pimentel V, Pingarilho M, Sebastiao C, Miranda M, Goncalves F, Cabanas J Viruses. 2024; 16(4).

PMID: 38675962 PMC: 11054263. DOI: 10.3390/v16040622.

Bangoura N, Diouara A, Cisse M, Ndiaye H, Mboup S, Ayouba A Afr J Lab Med. 2024; 4(1):168.

PMID: 38440313 PMC: 10911652. DOI: 10.4102/ajlm.v4i1.168.

Natural Polymorphisms D60E and I62V Stabilize a Closed Conformation in HIV-1 Protease in the Absence of an Inhibitor or Substrate.

Tran T, Fanucci G Viruses. 2024; 16(2).

PMID: 38400012 PMC: 10892587. DOI: 10.3390/v16020236.

References

Miller M, Margot N, Lu B, Zhong L, Chen S, Cheng A . Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004; 189(5):837-46. DOI: 10.1086/381784. View

Mihailidis C, Dunn D, Pillay D, Pozniak A . Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy. AIDS. 2008; 22(3):427-30. DOI: 10.1097/QAD.0b013e3282f3744f. View

Whitcomb J, Parkin N, Chappey C, Hellmann N, Petropoulos C . Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis. 2003; 188(7):992-1000. DOI: 10.1086/378281. View

von Wyl V, Ehteshami M, Symons J, Burgisser P, Nijhuis M, Demeter L . Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. J Infect Dis. 2010; 201(7):1054-62. DOI: 10.1086/651168. View

Wittkop L, Breilh D, da Silva D, Duffau P, Mercie P, Raymond I . Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. J Antimicrob Chemother. 2009; 63(6):1251-5. PMC: 2885067. DOI: 10.1093/jac/dkp114. View

Romano L, Venturi G, Bloor S, Harrigan R, Larder B, Major J . Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J Infect Dis. 2002; 185(7):898-904. DOI: 10.1086/339706. View

Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M . Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol. 2009; 83(22):11440-6. PMC: 2772690. DOI: 10.1128/JVI.01168-09. View

Kempf D, ISAACSON J, King M, Brun S, Xu Y, Real K . Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol. 2001; 75(16):7462-9. PMC: 114981. DOI: 10.1128/JVI.75.16.7462-7469.2001. View

Kagan R, Shenderovich M, Heseltine P, Ramnarayan K . Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci. 2005; 14(7):1870-8. PMC: 2253353. DOI: 10.1110/ps.051347405. View

10.

Garcia-Lerma J, MacInnes H, Bennett D, Weinstock H, Heneine W . Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. J Virol. 2004; 78(14):7545-52. PMC: 434071. DOI: 10.1128/JVI.78.14.7545-7552.2004. View

11.

Johnson V, Brun-Vezinet F, Clotet B, Gunthard H, Kuritzkes D, Pillay D . Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007; 15(4):119-25. View

12.

Kuritzkes D, Quinn J, Benoit S, Shugarts D, Griffin A, Bakhtiari M . Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS. 1996; 10(9):975-81. DOI: 10.1097/00002030-199610090-00007. View

13.

Lanier E, Ait-Khaled M, Scott J, Stone C, Melby T, Sturge G . Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir Ther. 2004; 9(1):37-45. DOI: 10.1177/135965350400900102. View

14.

Cooper D, Steigbigel R, Gatell J, Rockstroh J, Katlama C, Yeni P . Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008; 359(4):355-65. DOI: 10.1056/NEJMoa0708978. View

15.

Harrigan P, Stone C, Griffin P, Najera I, Bloor S, Kemp S . Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis. 2000; 181(3):912-20. DOI: 10.1086/315317. View

16.

Young T, Parkin N, Stawiski E, Pilot-Matias T, Trinh R, Kempf D . Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease. Antimicrob Agents Chemother. 2010; 54(11):4903-6. PMC: 2976162. DOI: 10.1128/AAC.00906-10. View

17.

von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, Battegay M . Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis. 2008; 46(8):1299-309. DOI: 10.1086/528863. View

18.

Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R . Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2010; 54(4):389-93. PMC: 2890029. DOI: 10.1097/QAI.0b013e3181c42ea4. View

19.

Cohen C, Andrade-Villanueva J, Clotet B, Fourie J, Johnson M, Ruxrungtham K . Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011; 378(9787):229-37. DOI: 10.1016/S0140-6736(11)60983-5. View

20.

Haubrich R, Kemper C, Hellmann N, Keiser P, Witt M, Forthal D . The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002; 16(15):F33-40. DOI: 10.1097/00002030-200210180-00001. View